Drug Profile
Research programme: serine racemase inhibitors - MGI GP
Latest Information Update: 20 Feb 2008
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer MGI GP
- Class Small molecules
- Mechanism of Action Serine racemase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurodegenerative disorders
Most Recent Events
- 31 Dec 2007 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
- 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma